Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 145 affiliates and a total of around 47,500 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of its net sales.
Company Growth (employees)
Type
Private
HQ
Ingelheim Am Rhein, DE
Founded
1885
Size (employees)
35,197 (est)
Boehringer Ingelheim was founded in 1885 and is headquartered in Ingelheim am Rhein, DE

Boehringer Ingelheim Office Locations

Boehringer Ingelheim has an office in Ingelheim am Rhein
Ingelheim am Rhein, DE (HQ)
173 Binger Str.

Boehringer Ingelheim Financials and Metrics

Summary Metrics

Founding Date

1885

Boehringer Ingelheim Median Salaries

Source: 39 public H-1B filings from Boehringer Ingelheim

Boehringer Ingelheim's Web-traffic and Trends

Boehringer Ingelheim Online and Social Media Presence

Boehringer Ingelheim News and Updates

Asthma’s a real bear in Boehringer Ingelheim’s new TV campaign for Spiriva Respimat

Want to know what asthma feels like? Try a crushing bear hug. That’s what patients told Boehringer Ingelheim, informing its latest campaign for Spiriva Respimat as a treatment for asthma. In new TV work for Spiriva Respimat, an asthma sufferer is locked in the grip of an actual large brown bear as h…

Geisinger, Boehringer Ingelheim collaborate on a risk-prediction model for type 2 diabetes

Work is aimed at preventing heart and kidney failure, two deadly conditions spurred by the chronic disease.

Boehringer Ingelheim highlights Stiolto in new COPD awareness film

Like many disease awareness films, Boehringer Ingelheim's new documentary about COPD tells stories through the experience of real patients. However, unlike most disease awareness films, this film also talks about Boehringer’s specific treatment, Stiolto Respimat.

EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point

LISBON, Portugal—Back in 2015, Boehringer Ingelheim and Eli Lilly were the first drugmakers to show that a diabetes med could cut the risk of cardiovascular death, and they’re still working to capitalize on that advantage.

Boehringer Ingelheim Company Life and Culture

You may also be interested in